Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | NOS2 | P35228 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | NPY2R | P49146 | 1/20 | 0.50 |
| ▸ | NPY4R | P50391 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | NRP1 | O14786 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1736042 | 1.00 | CYP2C19 (0.59) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL1736416 | 1.00 | CYP2C19 (0.59) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL29794337 | 0.97 | CYP2C19 (0.56) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL1736266 | 0.96 | NPY1R (0.55) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL1736568 | 0.91 | CYP2C19 (0.59) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL29506889 | 0.91 | NOS2 (0.55) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL1738257 | 0.90 | NPY1R (0.53) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL29355798 | 0.90 | NPY1R (0.51) | CYP2C19NOS2CYP1A2GLATSHR | |
| Thymotrinan SCHEMBL15532089 | 0.90 | NPY1R (0.53) | CYP2C19NOS2CYP1A2GLATSHR | |
| Thymotrinan SCHEMBL1738371 | 0.90 | NPY1R (0.53) | CYP2C19NOS2CYP1A2GLATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | AMGEN INC. (US) | 2025-12-04 | — | — | US | claimed |
| CN-118388590-A | Antarctic krill ACE (angiotensin converting enzyme) inhibitory peptide LFAGA, RDWPEGR, DWPEGR and application thereof | 中国水产科学研究院黄海水产研究所 | 2024-07-26 | — | — | CN | claimed |
| CN-117858890-A | Polypeptide compound and application thereof in treating enteritis | 四川好医生攀西药业有限责任公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117677302-A | Peptide compounds for flavor modulation | CJ第一制糖株式会社 | 2024-03-08 | — | — | CN | claimed |
| CN-117567562-A | Antarctic krill ACE (angiotensin converting enzyme) inhibitory peptide as well as preparation method and application thereof | 中国水产科学研究院黄海水产研究所 | 2024-02-20 | — | — | CN | claimed |
| US-12594227-B2 | Tetrapeptide and compositions comprising tetrapeptides | THE BOOTS COMPANY PLC (GB) | 2026-04-07 | — | — | US | disclosed |
| WO-2026046854-A1 | PEPTIDE CONTAINING HYDROGEL COMPOSITIONS | THE BOOTS COMPANY PLC (GB) | 2026-03-05 | — | — | WO | disclosed |
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | AMGEN INC. (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2025215348-A1 | SKIN WOUND TREATMENT | THE BOOTS COMPANY PLC (GB) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025215347-A1 | SKIN WOUND TREATMENT | THE BOOTS COMPANY PLC (GB) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025215346-A1 | SKIN WOUND TREATMENT | THE BOOTS COMPANY PLC (GB) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025215349-A1 | HAIR GROWTH RESTORATION | THE BOOTS COMPANY PLC (GB) | 2025-10-16 | — | — | WO | disclosed |
| WO-2022106054-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | THE BOOTS COMPANY PLC (GB) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022106055-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | THE BOOTS COMPANY PLC (GB) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022106056-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | THE BOOTS COMPANY PLC (GB) | 2022-05-27 | — | — | WO | disclosed |
| EP-4000598-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | The Boots Company plc (GB) | 2022-05-25 | — | — | EP | disclosed |
| EP-4001294-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | The Boots Company plc (GB) | 2022-05-25 | — | — | EP | disclosed |
| EP-4000595-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | The Boots Company plc (GB) | 2022-05-25 | — | — | EP | disclosed |
| EP-4000596-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | The Boots Company plc (GB) | 2022-05-25 | — | — | EP | disclosed |
| EP-4000597-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | The Boots Company plc (GB) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594227-B2 | Tetrapeptide and compositions comprising tetrapeptides | SRRM2, SGTA, QARS1 | CYP2C19 4876/4885NOS2 4194/4885CYP1A2 4838/4885 |
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | ARGLU1, ARG1, FCGRT | CYP2C19 4519/4885NOS2 889/4885CYP1A2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.